Development of Improved Chromatographic Methods for the Separation of Synthetic Peptides Medications and Associated Impurities

Significance of the Topic

Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as pivotal therapeutics for obesity and type II diabetes management. Ensuring high purity of these synthetic peptides and their related impurities is critical for patient safety and compliance with regulatory standards.

Objectives and Overview of the Study

This work aimed to develop a single, robust HPLC-UV/MS method capable of separating an expanded panel of GLP-1 agonists, glucagon, and their common desamido impurities. A systematic method development protocol was applied alongside a novel surface modification technology to achieve sensitive, reproducible separations.

Methodology and Instrumentation

• Screening: Four reversed-phase columns (including XSelect Premier Peptide CSH C18) and two mobile phase additives (0.1% formic acid vs. 0.1% trifluoroacetic acid) were evaluated using water (A) and acetonitrile (B) gradients.
• Optimization: Gradient slope, column temperature, flow rate, and injection volume were refined to maximize resolution and speed.
• Surface Technology: A hybrid organic/inorganic ethylene-bridged siloxane coating was applied to mitigate peptide–metal interactions and improve chromatographic performance.
• Detection: Ultraviolet (UV) detection was combined with mass spectrometry (MS) for peak identification and purity assessment.

Main Results and Discussion

• The XSelect Premier Peptide CSH C18 column with formic acid mobile phases provided the fastest separations and highest resolution for glucagon and its four desamido impurities.
• Baseline separation of glucagon and all desamido forms was achieved, confirmed by UV spectra and MS fragment data.
• Compared to conventional stainless-steel hardware, the novel surface treatment yielded up to 28% increase in peak area, 57% increase in peak height, and a 13% reduction in tailing for multiple GLP-1s including liraglutide and semaglutide.
• Stacked chromatograms illustrated clear selectivity differences across column and mobile phase combinations, guiding the final method selection.

Benefits and Practical Applications

This unified method streamlines quality control workflows by enabling simultaneous analysis of multiple GLP-1 therapeutics and impurities. Enhanced peak performance and reproducibility support regulatory compliance and improve assay sensitivity in pharmaceutical QC settings.

Future Trends and Potential Applications

• Extension of the protocol to additional peptide therapeutics and impurity profiles.
• Further refinements in surface chemistries to reduce nonspecific adsorption and enhance throughput.
• Integration with high-resolution MS and automated method scouting for rapid assay development.
• Adoption of similar approaches in biotherapeutic and biosimilar analytical workflows.

Conclusion

A systematic, DOE-inspired approach combined with advanced column surface technology produced a versatile HPLC-UV/MS method for GLP-1 agonists and their impurities. The optimized conditions deliver reproducible, high-resolution separations that meet current regulatory guidelines and support robust pharmaceutical quality control.

Reference

1. Holz G, Chepurny O. Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus. Current Medicinal Chemistry. 2003 Nov;10(22):2471–83.
2. Wojtara MS, Mazumder A, Syeda Y, Mozgała N. Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management. Advances in Medicine. 2023 Sep 20;2023(Article ID 9946924):1–7.
3. United States Pharmacopeia. Exenatide Injection USP Monograph. 2019.
4. United States Pharmacopeia. Glucagon USP Monograph. 2022.
5. Kuna AK, Ganapathi S, Radha G. A Novel RP-HPLC Method Development and Forced Degradation Studies for Semaglutide in API and Pharmaceutical Dosage Forms. International Journal of Research in Pharmaceutical Sciences. 2019 Apr;10(2):865–73.
6. Pedaprolu JN et al. A New Stability-Indicating and Validated RP-HPLC Method for Liraglutide in Bulk and Dosage Forms. Eurasian Journal of Analytical Chemistry. 2016 Dec 8;12(2):31–44.
7. Pang E. Assessing Immunogenicity Risk of Peptides: the Synthetic Peptide Guidance and PSGs. FDA SBIA 2020.
8. Birdsall R, Kellet J, Ippoliti S, Qing Yu Y. Increasing Recovery and Chromatographic Performance of “Acidic” Peptides Using Waters ACQUITY Premier Solution. Waters Corporation; 2021.
9. Bigos P, Birdsall R, Walter T. MaxPeak Premier Solutions: Improving Consumer Safety Through Innovative Science. Waters Corporation; 2021.